Precision Oncology ITM is advancing a broad precision oncology pipeline with multiple Phase 3 studies that pair high-quality radioisotopes with targeting molecules, creating partnership opportunities in late-stage development, co-development, licensing and market access for hard-to-treat tumors.

Global Manufacturing With a stated focus on excellence in development, production and global supply, supported by two decades of radiopharma expertise and an established global network, there are strong selling points for contract manufacturing, supply agreements and strategic collaborations to scale radiopharmaceutical production.

Strong Capital Backing Major funding activity including a significant investment from Blue Owl Capital in 2025, plus recognition such as the Marie Curie Award, signals financial strength and credibility that can underpin co-development deals, long-term partnerships and market expansion initiatives.

Competitive Edge ITM maintains a central industry position in radiopharma with long-standing expertise and dosimetry leadership through COMPETE, offering a credible value proposition for customers seeking reliable isotope supply chains, dosimetry services and scalable alpha-therapy workflows.

Clinical Partnerships Robust COMPETE study data demonstrating improved clinical signals and patient-reported quality of life, showcased at leading oncology conferences, can fuel co-development, licensing and market-access conversations with oncologists, hospitals and pharma partners.